Post by Coultreon Biopharma

Our team is attending the ECCO conference next week in Stockholm! Pierre Raboisson, John-Paul Gallivan and Fabrice A. Kolb will be representing Onco3R during the poster session on Friday Feb 20th at 12:40-13:40. They will be sharing exciting updates about our Phase1 clinical results of our first-in-class SIK3 inhibitor O3R-5671, demonstrating optimal pharmacokinetics and potent and sustained pharmacodynamic activity. 💡 Please join them at the poster for an in-depth scientific exchange! #ECCO26 #IBDCommunity #ECCOCongress #Onco3R #SIK3 #FirstInClass